



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 06 March 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

As a part of Eris Groups’ internal structuring of the holdings, the Company has transferred 100% of its holdings in the below mentioned entities to Eris Therapeutics Limited (“ETL”), a wholly-owned subsidiary:

- Eris Oaknet Healthcare Private Limited (“EOHPL”), wholly-owned subsidiary
- Aprica Healthcare Limited (“AHL”), wholly-owned subsidiary

In accordance with requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, details attached herein shall be taken on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493
Encl: As above

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Sale or disposal of unit(s) or division(s), whole or substantially the whole of the undertaking(s) or subsidiary of the listed entity, sale of stake in the associate company of the listed entity:

Sr. No.	Particulars	Details		
			Total Revenue	Networth
1.	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	AHL	Rs. 604.05 mn	Rs. 805.75 mn
			3.0%	2.5%
		EOHPL	Rs. 726.47 mn	Rs. 633.33 mn
		3.6%	2.0%	
2.	date on which the agreement for sale has been entered into	06-03-2025		
3.	the expected date of completion of sale/disposal;	31-03-2025		
4.	consideration received from such sale/disposal	8619.14 million		
5.	brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	NA		
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes The transaction is done on Arms Length Basis		
7.	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable		
8.	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable		

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867